These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 6385429)

  • 1. The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis.
    Ellard GA
    Tubercle; 1984 Sep; 65(3):211-27. PubMed ID: 6385429
    [No Abstract]   [Full Text] [Related]  

  • 2. Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis.
    Gurumurthy P; Krishnamurthy MS; Nazareth O; Parthasarathy R; Sarma GR; Somasundaram PR; Tripathy SP; Ellard GA
    Am Rev Respir Dis; 1984 Jan; 129(1):58-61. PubMed ID: 6367570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis].
    Ellard GA
    Rev Mal Respir; 1984; 1(4):207-19. PubMed ID: 6505358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis].
    Ellard GA
    Cas Lek Cesk; 1984 Feb; 123(6):158-64. PubMed ID: 6697364
    [No Abstract]   [Full Text] [Related]  

  • 5. The incidence of the acetylator phenotype of isoniazid in healthy and in pulmonary tuberculosis subjects in Bihar.
    Sinha CP; Sinha S; Sinha KP
    J Assoc Physicians India; 1978 May; 26(5):353-60. PubMed ID: 730714
    [No Abstract]   [Full Text] [Related]  

  • 6. The hepatotoxicity of isoniazid among the three acetylator phenotypes.
    Ellard GA; Girling DJ; Nunn AJ
    Am Rev Respir Dis; 1981 May; 123(5):568-70. PubMed ID: 7235381
    [No Abstract]   [Full Text] [Related]  

  • 7. Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis.
    Ellard GA
    Clin Pharmacol Ther; 1976 May; 19(5 Pt 2):610-25. PubMed ID: 773583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acetylation phenotype and hepatotoxicity in the treatment of tuberculosis in children.
    Martinez-Roíg A; Camí J; Llorens-Terol J; de la Torre R; Perich F
    Pediatrics; 1986 Jun; 77(6):912-5. PubMed ID: 3487069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Incidence of hepatic changes in relation to the isoniazid acetylator phenotype].
    Pilheu JA; De Salvo MC; Manchinu I; de Negroni NR; Szemzo J
    Medicina (B Aires); 1980; 40(4):382-6. PubMed ID: 7207170
    [No Abstract]   [Full Text] [Related]  

  • 10. [Clinical pharmacology of isoniazid (a review of the literature)].
    Ivleva AIa
    Probl Tuberk; 1979 Jan; (1):18-26. PubMed ID: 368763
    [No Abstract]   [Full Text] [Related]  

  • 11. Acetylator phenotyping with sulphadimidine in patients receiving isoniazid.
    Ylitalo P; Auterinen L; Marttinen A; Koivula T
    Int J Clin Pharmacol Res; 1984; 4(2):141-4. PubMed ID: 6469440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis.
    Grönhagen-Riska C; Hellstrom PE; Fröseth B
    Am Rev Respir Dis; 1978 Sep; 118(3):461-6. PubMed ID: 707874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Determination of the phenotype of INH inactivation in pulmonary tuberculosis by means of an indirect method on the model of sulfamethazine].
    Powłowska I; Rakowska Z
    Pneumonol Pol; 1978 Aug; 46(8):605-12. PubMed ID: 714703
    [No Abstract]   [Full Text] [Related]  

  • 14. Determination of the isoniazid acetylator phenotype in a West African population.
    Salako LA; Aderounmu AF
    Tubercle; 1977 Jun; 58(2):109-12. PubMed ID: 878015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isoniazid acetylation rate and development of antinuclear antibodies upon isoniazid treatment.
    Alarcón-Segovia D; Fishbein E; Alcalá H
    Arthritis Rheum; 1971; 14(6):748-52. PubMed ID: 5316358
    [No Abstract]   [Full Text] [Related]  

  • 16. Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide.
    Parthasarathy R; Sarma GR; Janardhanam B; Ramachandran P; Santha T; Sivasubramanian S; Somasundaram PR; Tripathy SP
    Tubercle; 1986 Jun; 67(2):99-108. PubMed ID: 3775870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isoniazid acetylator phenotypes of Nigerians.
    Afonja AO; Arhavwarien ED; Okotore RO; Femi-Pearse D
    Niger Med J; 1979 Jan; 9(1):86-8. PubMed ID: 463346
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison between serum and urinary sulphadimidine acetylation as predictors of isoniazid acetylator status in patients with pulmonary tuberculosis.
    Singh SP; Pande JN; Khilnani GC; Kailash S
    Indian J Chest Dis Allied Sci; 1996; 38(1):5-11. PubMed ID: 16892742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype.
    Yamamoto T; Suou T; Hirayama C
    Hepatology; 1986; 6(2):295-8. PubMed ID: 3957235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Rate of acetylation of isoniazid in pulmonary tuberculosis and its relationship with effect and side-effects of treatment (author's transl)].
    Zhang LX
    Zhonghua Jie He He Hu Xi Xi Ji Bing Za Zhi; 1981 Dec; 4(6):349-51. PubMed ID: 7344873
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.